Supervised care
Spravato is given in a certified healthcare setting under professional supervision.
Spravato® (esketamine)
A different treatment option for certain forms of depression.
Spravato (esketamine) is a prescription nasal spray approved by the FDA for certain depressive conditions in adults. It may be an option for eligible individuals following a thorough clinical evaluation.
Prescription nasal spray
Spravato contains esketamine, administered as a nasal spray.
FDA-approved indications
Approved for certain depressive conditions in adults.
Certified setting
Given under professional supervision, with required monitoring.
Understanding Spravato
What Spravato is — and how it is given.
Spravato contains esketamine, a medication administered in a certified healthcare setting under professional supervision.
It has FDA-approved indications that include treatment-resistant depression in adults, as well as depressive symptoms in adults with major depressive disorder with acute suicidal ideation or behavior under specific conditions.
Approved for specific adults
An FDA-approved indication is not a general recommendation. A qualified clinician decides whether it applies to you.
Approval is one part of the picture.
A common confusion
How is it different from ketamine?
Although the names are related, ketamine and Spravato are not interchangeable. They have distinct regulatory approvals, formulations, administration requirements, and treatment considerations.
Ketamine
Spravato®
Regulatory approval
Approved as an anesthetic; psychiatric use is off-label.
FDA-approved indications for certain depressive conditions in adults.
Formulation
Determined by the treating clinician and confirmed protocol.
Prescription nasal spray containing esketamine.
Administration & monitoring
Set by the clinician and the treatment protocol.
Given in a certified setting with required monitoring.
Distribution
Prescribed through the treating team.
Subject to a restricted distribution program.
Spravato is subject to specific safety monitoring and a restricted distribution program.
What to expect
Care that is supervised from start to finish.
Treatment with Spravato follows a defined path, from evaluation to follow-up.
- 1
Evaluation
A care team evaluates medical history, previous treatments, and other relevant factors to determine whether Spravato may be suitable.
- 2
Administration
Treatment involves administration under supervision in a certified healthcare setting.
- 3
Monitoring
Required monitoring follows administration, as directed by the treating team.
- 4
Going home
Patients must arrange transportation home and should follow the treating team's instructions.
Questions
Spravato questions, answered.
Educational answers only — your clinician will guide decisions about your care.
Depression is often described as treatment-resistant when symptoms have not responded adequately to previous treatment attempts. A clinician determines whether that applies to you by reviewing your history and the treatments you have already tried.
Although the names are related, ketamine and Spravato are not interchangeable. They have distinct regulatory approvals, formulations, administration requirements, and treatment considerations. Spravato is also subject to specific safety monitoring and a restricted distribution program.
Yes. Spravato is administered in a certified healthcare setting under professional supervision, and monitoring follows administration. Patients must arrange transportation home and should follow the treating team's instructions.
Spravato can cause side effects and is not appropriate for everyone. Potential risks depend on your medical and psychiatric history. These are reviewed with you during the evaluation, and monitoring is part of the treatment process.
A care team evaluates medical history, previous treatments, and other relevant factors to determine whether Spravato may be suitable. Eligibility is determined only by a qualified clinician.
Coverage varies by plan and by individual circumstances. The Neurobody team can help you understand what to confirm with your insurance provider before treatment decisions are made.
Begin with a conversation
Explore whether Spravato may be an appropriate treatment option.
Speak with the Neurobody team in Atlanta. Every conversation begins with a thorough psychiatric evaluation — not a quick decision.
Request an EvaluationEducational information only. All treatment decisions are made by qualified clinicians.